Cartherics and Catalent have strengthened their collaboration to accelerate the development and future commercialisation of advanced immune cell therapies.

Entropy Neurodynamics has taken another step forward in its clinical exploration of psychedelic-assisted therapy, announcing that the third patient in its trial of TRP-8803 has completed dosing and achieved what the company describes as a full and controlled psychedelic response.

The companies said feedback from the initial limited launch suggests that this approach is resonating, with more than 80 per cent of caregivers reporting satisfaction, particularly noting the convenience and portability of individual packet dosing. 

The ten-year contract, valued at up to $25.5 million, is designed to ensure that critical treatment resources are immediately available when large-scale burn incidents occur, a scenario where speed and scalability can determine survival outcomes.

Chairman Russell Howard and Chief Executive Marc Voigt acknowledged the disappointment while emphasising that the broader scientific platform remains intact.

Orthocell (ASX:OCC) has joined a cohort of Australian life sciences companies seeking to calm investor nerves over looming US tariff measures, arguing that its business will remain largely untouched even as Washington signals a tougher stance on imported pharmaceuticals.

Mesoblast (ASX:MSB) has received clearance from the US Food and Drug Administration to proceed directly to a registrational trial of its therapy, Ryoncil, in children with Duchenne muscular dystrophy.

The Board of MTPConnect has announced the appointment of Chief Executive Officer Stuart Dignam as a Director, marking a significant milestone as the organisation moves into its second decade of operation.

Telix Pharmaceuticals (ASX:TLX) has delivered robust revenue growth alongside meaningful progress across its therapeutics pipeline in the three months to the end of March 2026.

The company said it has begun reviewing the details of the announcement, with an initial assessment indicating that the majority of its product portfolio in the US market is unlikely to fall within the scope of the tariffs.

The Melbourne-based company had been studying narmafotinib in combination with the widely used but aggressive mFOLFIRINOX regimen in patients with advanced pancreatic cancer.

Vitura Health (ASX:VIT) has appointed experienced healthcare executive Justin James as its new chief executive officer, marking a significant leadership shift as the company positions itself for further expansion in emerging therapies and digital health services.

Algorae Pharmaceuticals (ASX:1AI) has moved to strengthen its financial footing, announcing a $3.9 million capital raise to scale its commercial operations and advance its artificial intelligence-driven research pipeline.

Clinuvel Pharmaceuticals (ASX:CUV) used one of the world’s largest dermatology forums to sharpen its profile in pigmentary disorders, presenting new clinical insights and reinforcing the positioning of its lead therapy across both approved and investigational uses.

Arovella Therapeutics (ASX:ALA) has reported new preclinical data that strengthens the case for its engineered immune cell platform, demonstrating sustained and enhanced killing of pancreatic and gastric cancer cells in laboratory studies.

In laboratory models of human neurons, NUZ-001 appears to activate multiple internal systems that clear misfolded and aggregated proteins, a hallmark of conditions such as amyotrophic lateral sclerosis.

Telix Pharmaceuticals (ASX:TLX) has moved to bolster its board and leadership succession plans with the appointment of veteran healthcare executive David Gill as a non-executive director.

In new data from ongoing investigator-initiated trials in China, the company’s experimental CAR-T therapy, BZDS1901, demonstrated tumour shrinkage and even complete clearance in a subset of heavily pretreated patients.